未切除的高分化和低分化肺腺癌生存率的比较。
Comparison of survival in nonresected well differentiated and poorly differentiated adenocarcinoma of the lung.
作者信息
Saijo N, Niitani H, Tominaga K, Eguchi K, Koketsu H, Fujino T, Ishikawa S
出版信息
J Cancer Res Clin Oncol. 1980;97(1):71-9. doi: 10.1007/BF00411280.
One hundred nineteen cases of advanced adenocarcinoma of the lung were divided into well differentiated adenocarcinoma (72 cases) and poorly differentiated adenocarcinoma (47 cases) histologically and/or cytologically. The median survival of 72 cases of well differentiated adenocarcinoma (7.9 months) was significantly (P less than 0.025) longer than that of poorly differentiated adenocarcinoma (4.9 months) irrespective of stage, difference in treatment regimen, or response to treatment. In 9 evaluable cases, the objective response rate to chemotherapy was 25% (6/24) in poorly differentiated adenocarcinoma and 11.3% (8/71) in well differentiated adenocarcinoma, respectively. In 45 patients who received a combination of chemotherapy and radiotherapy, the median survival of 22 well differentiated adenocarcinomas (11.8 months) was significantly (P less than 0.05) longer than than of 23 poorly differentiated adenocarcinomas (5.6 months). The same tendency was observed in 74 patients who received chemotherapy alone. Analysis based on the grade of differentiation is essential for the accurate assessment of the efficacy of treatment in adenocarcinomas of the lung.
119例晚期肺腺癌患者在组织学和/或细胞学上被分为高分化腺癌（72例）和低分化腺癌（47例）。72例高分化腺癌患者的中位生存期为7.9个月，无论分期、治疗方案差异或对治疗的反应如何，均显著长于低分化腺癌患者的4.9个月（P<0.025）。在9例可评估病例中，低分化腺癌对化疗的客观缓解率为25%（6/24），高分化腺癌为11.3%（8/71）。在45例接受化疗和放疗联合治疗的患者中，22例高分化腺癌的中位生存期为11.8个月，显著长于23例低分化腺癌的5.6个月（P<0.05）。在74例仅接受化疗的患者中也观察到相同趋势。基于分化程度的分析对于准确评估肺腺癌的治疗效果至关重要。
Zotero 插件